The magazine is published online only. The frequency of releases is 4 times a year.                             

The journal publishes the latest research in the field of clinical and basic medicine:pathological physiology, internal medicine and surgery.

Preview

Baikal Medical Journal

Advanced search

ANTIOXIDANTS AS POTENTIAL BIOMARKERS OF NONALCOHOLIC FATTY LIVER DISEASE STAGES

https://doi.org/10.57256/2949-0715-2023-4-24-32

Abstract

Nonalcoholic fatty liver disease is a complex and multifactorial pathology associated with multiple epigenetic, genetic and environmental factors, and its pathogenesis is still not fully understood. Nonalcoholic fatty liver disease begins with simple steatosis and progresses to nonalcoholic steatohepatitis, which is characterized by signs of oxidative stress, increased lipid peroxidation activity, inflammation, fibrosis, and apoptosis. Antioxidant deficiency is important in the pathogenesis of nonalcoholic fatty liver disease, as it is they that cause the transition of steatosis to steatohepatitis in nonalcoholic fatty liver disease. Markers of antioxidant defense are used to assess disease progression and pathologic state. This article reviews several key biomarkers of antioxidant defense that can be investigated in clinical practice. 
Determination of these biomarkers in nonalcoholic fatty liver disease can be used for diagnostic purposes.

About the Authors

Sofya D. Kravchenko
Irkutsk State Medical University
Russian Federation


Natalia M. Kozlova
Irkutsk State Medical University
Russian Federation


Olesya V. Tirikova
Irkutsk State Medical University
Russian Federation


Vera Il. Bakhtairova
Irkutsk State Medical University
Russian Federation


References

1. 1. Ивашкин В.Т., Маевская М.В., Жаркова М.С. и др. Клинические рекомендации Российского общества по изучению печени, Российской гастроэнтерологической ассоциации, Российской ассоциации эндокринологов, Российской ассоциации геронтологов и гериатров и Национального общества профилактической кардиологии по диагностике и лечению неалкогольной жировой болезни печени. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2022;32(4):104-140

2. [Ivashkin V.T., Maevskaya M.V., Zharkova M.S. et al. Clinical recommendations of the Russian Society for Liver Research, Russian Gastroenterological Association, Russian Association of Endocrinologists, Russian Association of Gerontologists and Geriatrics and National Society of Preventive Cardiology on the diagnosis and treatment of nonalcoholic fatty liver disease. Russian Journal of Gastroenterology, Hepatology, and Coloproctology. 2022;32(4):104-140. (In Russian)].DOI:10.22416/1382-4376-2022-32-4-104-140

3. Маевская М.В., Ивашкин В.Т. Печень и питание. Оптимальная диета при неалкогольной жировой болезни печени. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2018;28(5):105-116 [Mayevskaya M.V., Ivashkin V.T. Liver and Nutrition. An Optimal Diet for Non-Alcoholic Fatty Liver Disease. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2018;28(5):105-116 (In Russian)]. DOI:10.22416/1382-4376-2018-28-5-105-116

4. Shao JS, Aly ZA, Lai CF, et al. Vascular Bmp Msx2 Wnt signaling and oxidative stress in arterial calcification. Ann N Y Acad Sci. 2007;1117:40-50. DOI:10.1196/annals.1402.075.

5. Ha HL, Shin HJ, Feitelson MA, Yu DY. Oxidative stress and antioxidants in hepatic pathogenesis. World J Gastroenterol. 2010;16(48):6035-6043. DOI:10.3748/wjg.v16.i48.6035

6. Sies H, Berndt C, Jones DP. Oxidative Stress. Annu Rev Biochem. 2017;20;(86):715-748. DOI:10.1146/annurev-biochem-061516-045037

7. Мишина Е.Е., Майоров А.Ю., Богомолов П.О., и др. Неалкогольная жировая болезнь печени: причина или следствие инсулинорезистентности? Сахарный диабет. 2017;20(5):335-343. [Mishina E.E., Mayorov A.Y., Bogomolov P.O., etc. Nonalcoholic fatty liver disease: cause or consequence of insulin resistance? Diabetes mellitus. 2017;20(5):335-343. (In Russian)] DOI:10.14341/DM9372

8. Seki S, Kitada T, Yamada T, et al. In situ detection of lipid peroxidation and oxidative DNA damage in non-alcoholic fatty liver diseases. J Hepatol. 2002; 37(1):56-62. DOI:10.1016/s0168-8278(02)00073-9

9. Janos F, Geza C, Andras V. Free Radical Reactions in Medicine. Springer Berlin (Heidelberg). 2011;(12):199. DOI:10.1007/978-3-642-83104-1

10. Galano A, Alvarez-Idaboy JR. Glutathione: mechanism and kinetics of its non-enzymatic defense action against free radicals. RSC Advances. 2011; (1):1763–1771. DOI:10.1039/C1RA00474C

11. Anderson M. Glutathione: an overview of biosynthesis and modulation. Chem Biol Interact. 1998;(111-112):1–14. DOI:10.1016/s0009-2797(97)00146-4

12. Winterbourn C. Superoxide as an intracellular radical sink. Free Radical Biology and Medicine. 1993;(14), 85–90. DOI:10.1016/0891-5849(93)90512-s.

13. Owen J, Butterfield D. Measurement of oxidized/reduced glutathione ratio. Methods Mol Biol. 2010;(648):269-77. DOI:10.1007/978-1-60761-756-3_18.

14. Aquilano K, Baldelli S, Ciriolo M. Glutathione: new roles in redox signaling for an old antioxidant. Front Pharmacol. 2014;(5):196. DOI:10.3389/fphar.2014.00196.

15. Franco R, Cidlowski J. Apoptosis and glutathione: beyond an antioxidant. Cell Death and Differentiation. 2009;(16):1303–1314. DOI:10.1038/cdd.2009.107.

16. Townsend D, Tew K, Tapiero H. The importance of glutathione in human disease. Biomed Pharmacother. 2003;(57):145-55. DOI:10.1016/s0753-3322(03)00043-x.

17. Franco R, Cidlowski J. Apoptosis and glutathione: beyond an antioxidant. Cell Death and Differentiation. 2009; (16):1303–1314. DOI:10.1038/cdd.2009.107.

18. Board P, Menon D. Glutathione transferases, regulators of cellular metabolism and physiology. Biochimica et Biophysica Acta. 2013;1830 (5); 3267–3288. DOI:10.1016/j.bbagen.2012.11.019.

19. Pigeolet E, Corbisier P, Houbion A, etc. Glutathione peroxidase, superoxide dismutase, and catalase inactivation by peroxides and oxygen derived free radicals. Mech Ageing Dev. 1990;51(3):283-97. DOI:10.1016/0047-6374(90)90078-t.

20. Deponte M. Glutathione catalysis and the reaction mechanisms of glutathione-dependent enzymes. Biochim Biophys Acta. 2013;1830(5):3217-66. DOI:10.1016/j.bbagen.2012.09.018.

21. Flohe L, Ursini F. Peroxidase: a term of many meanings. Antioxid Redox Signal. 2008;10(9):1485-90. DOI:10.1089/ars.2008.2059. PMID: 18479208.

22. Flohe L, Günzler WA. Assays of glutathione peroxidase. Methods Enzymol. 1984;(105):114-21. DOI:10.1016/s0076-6879(84)05015-1.

23. Czeczot H, Scibior D, Skrzycki M, et al. Glutathione and GSH-dependent enzymes in patients with liver cirrhosis and hepatocellular carcinoma. Acta Biochim Pol. 2006;53 (1) :237-41.

24. Townsend DM, Tew KD, Tapiero H. The importance of glutathione in human disease. Biomed Pharmacother. 2003;57(3-4):145-55. DOI:10.1016/s0753-3322(03)00043-x.

25. Chai Y.C., Ashraf S.S., Rokutan K., etc. S-thiolation of individual human neutrophil proteins including actin by stimulation of the respiratory burst: evidence against a role for glutathione disulfide. Arch Biochem Biophys. 1994; 310(1):273-81. DOI:10.1006/abbi.1994.1167

26. Dentico P, Volpe A, Buongiorno R, etc. Glutathione in the treatment of chronic fatty liver diseases. Recenti Prog Med. 1995;86(7-8):290-3.

27. Rolo AP, Teodoro JS, Palmeira CM. Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis. Free Radic Biol Med. 2012;52(1):59-69. DOI:10.1016/j.freeradbiomed.2011.10.003

28. Hardwick RN, Fisher CD, Canet MJ, et al. Diversity in antioxidant response enzymes in progressive stages of human nonalcoholic fatty liver disease. Drug Metab Dispos. 2010;38(12):2293-301. DOI:10.1124/dmd.110.035006.

29. Ismail N, Okasha S, Dhawan A, et al. Glutathione peroxidase, superoxide dismutase and catalase activities in hepatic tissue from children with glycogen storage disease. Archs Med Sci. 2009;(5): 86-90.

30. Sies H, Stahl W. Vitamins E and C, beta-carotene and other carotenoids as antioxidants. Am J Clin Nutr. 1995;62;(6):1315S-1321S. DOI:10.1093/ajcn/62.6.1315S.

31. Burton GW, Ingold KU. Autooxidation of biological molecules. The antioxidant activity of vitamin E and related chain-breaking phenolic antioxidants in vitro. Journal of the American Chemical Society.1981; (103): 6472-7.

32. Cankurtaran M, Kav T, Yavuz B. et al. Serum vitamin-E levels and its relation to clinical features in nonalcoholic fatty liver disease with elevated ALT levels. Acta Gastroenterol Belg. 2006;69(1):5-11.

33. Yamamoto Y, Yamashita S, Fujisawa A, et al. Oxidative stress in patients with hepatitis, cirrhosis, and hepatoma evaluated by plasma antioxidants. Biochem Biophys Res Commun. 1998;247(1):166-70. DOI:10.1006/bbrc.1998.8752.

34. Yesilova Z, Yaman H, Oktenli C, et al. Systemic markers of lipid peroxidation and antioxidants in patients with nonalcoholic Fatty liver disease. Am J Gastroenterol. 2005;100(4):850-5. DOI:10.1111/j.1572-0241.2005.41500.x.

35. Салль Т.С., Щербакова Е.С., Ситкин С.И., и др. Молекулярные механизмы развития неалкогольной жировой болезни печени. Профилактическая медицина. 2021;24(4):120 131. Sall T.S., Shcherbakova E.S., Sitkin S.I., et al. Molecular mechanisms of non - alcoholic fatty liver disease development. Profilakticheskaya Meditsina. 2021;24(4):120 131. (In Russian)] DOI:10.17116/profmed202124041120

36. Li ZZ, Berk M, McIntyre TM, et al. Hepatic lipid partitioning and liver damage in nonalcoholic fatty liver disease: role of stearoyl-CoA desaturase. J Biol Chem. 2009;284(9):5637-44. DOI:10.1074/jbc.M807616200.

37. Жаворонок Т. В., Степовая Е. А., Рязанцева Н. В. и др. Нарушение окислительного метаболизма при острых воспалительных заболеваниях. Клин. лаб. диагн. 2006;(12):10-14. [Zhavoronok T.V., Stepova E. A., Ryazantseva N. V. et al. The disturbance of oxidative metabolism in acute inflammatory diseases. Clin. lab. diag. 2006;(12):10-14 (In Russian)]

38. Тирикова О.В., Козлова Н.М., Кравченко С.Д., и др. Связь неалкогольной жировой болезни печени с сердечно-сосудистой патологией по данным аутопсии. Экспериментальная и клиническая гастроэнтерология, 2022; 7(203):38-44. [Tirikova O.V., Kozlova N.M., Kravchenko S.D. Association of non-alcoholic fatty liver disease with cardiovascular disease according to autopsy data. Experimental and Clinical Gastroenterology. 2022;7(203):38-44 (In Russian)]. DOI:10.31146/1682-8658-ecg-203-7-38-44.

39. Mazzolini G, Sowa JP, Atorrasagasti C, Kücükoglu Ö, Syn WK, Canbay A. Significance of Simple Steatosis: An Update on the Clinical and Molecular Evidence. Cells. 2020;9(11):2458. DOI: 10.3390/cells9112458.

40. Кормош Н. Г. Физиологическая роль активных форм кислорода на клеточном уровне и организма в целом - взгляд клинициста. Ч. 2. Российский биотерапевтический журнал. 2012;11(1):85-90 [Kormosh, N. G. Physiologic role of reactive oxygen species at the cellular level and the organism as a whole - a clinician's view. Russian Biotherapeutic Journal 2012;11(1):85-90].

41. Monserrat-Mesquida M, Quetglas-Llabrés M, Capó X, et al. Metabolic Syndrome is Associated with Oxidative Stress and Proinflammatory State. Antioxidants (Basel). 2020;9(3):236. DOI: 10.3390/antiox9030236.

42. Kumar A, Sharma A, Duseja A, et al. Patients with Nonalcoholic Fatty Liver Disease (NAFLD) have Higher Oxidative Stress in Comparison to Chronic Viral Hepatitis. J Clin Exp Hepatol. 2013;3(1):12-8. DOI: 10.1016/j.jceh.2012.10.009.

43. Köroğlu E, Canbakan B, Atay K, Hatemi İ, Tuncer M, Dobrucalı A, Sonsuz A, Gültepe I, Şentürk H. Role of oxidative stress and insulin resistance in disease severity of non-alcoholic fatty liver disease. Turk J Gastroenterol. 2016;27(4):361-6. DOI: 10.5152/tjg.2016.16106.

44. Koliaki C, Szendroedi J, Kaul K, et al. Adaptation of hepatic mitochondrial function in humans with non-alcoholic fatty liver is lost in steatohepatitis. Cell Metab. 2015;21(5):739-46. DOI:10.1016/j.cmet.2015.04.004.

45. Videla LA, Rodrigo R, Orellana M,et al. Oxidative stress-related parameters in the liver of non-alcoholic fatty liver disease patients. Clin Sci (Lond). 2004;106(3):261-8. DOI: 10.1042/CS20030285.

46. Leghi GE, Domenici FA, Vannucchi H. Influence Of Oxidative Stress And Obesity In Patients With Nonalcoholic Steatohepatitis. Arq Gastroenterol. 2015;52(3):228-33. DOI: 10.1590/S0004-28032015000300014.


Review

For citations:


Kravchenko S., Kozlova N., Tirikova O., Bakhtairova V. ANTIOXIDANTS AS POTENTIAL BIOMARKERS OF NONALCOHOLIC FATTY LIVER DISEASE STAGES. Baikal Medical Journal. 2023;2(4):24-32. https://doi.org/10.57256/2949-0715-2023-4-24-32

Views: 1846


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2949-0715 (Online)

Irkutsk State Medical University

Irkutsk Scientific Center for Surgery and Traumatology